Obstetrics & Gynecology, Wayne State University School of Medicine, Detroit, MI 48201, USA.
Neurotoxicol Teratol. 2010 Nov-Dec;32(6):605-10. doi: 10.1016/j.ntt.2010.05.006. Epub 2010 May 27.
Our objective was to assess the effects of repeated antenatal corticosteroid treatments on the neonatal auditory brainstem response (ABR), a sensitive measure of neonatal brain maturity and auditory function. To achieve this, we performed and blindly evaluated neonatal ABRs on a subset of infants delivering within a multicenter randomized placebo-controlled clinical trial comparing single versus repeated courses of antenatal corticosteroid treatments for women at 23-31 weeks gestation who remained at increased risk for preterm birth. The women were randomly assigned to either the single or the repeated antenatal corticosteroid treatment group. Women in the repeated antenatal corticosteroid group received weekly antenatal corticosteroid treatments until 34 weeks gestation or until they reached a study-determined limited number of courses, whereas women in the single antenatal corticosteroid group received an initial course of corticosteroid followed by weekly placebo injections. We performed ABR testing on their infants prior to discharge. The latencies of waves I, III and V and the peak-to-trough amplitudes of waves I and V were compared between those in the single (n=27) and repeated antenatal corticosteroid treatment (n=24) groups. The majority of repeated antenatal corticosteroid infants (20 of 24) were exposed to ≥ 4 antenatal corticosteroid treatments. Even though gestational age was similar between our subset of single and repeated antenatal corticosteroid treatment groups, infant birth weight and length and head circumference were significantly smaller in the repeated antenatal corticosteroid group (p <0.05). Despite these differences in birth sizes, there were no significant group differences in the ABR wave latencies or amplitudes. We concluded that our repeated antenatal corticosteroid treatments, in comparison to a single treatment, did not significantly benefit or harm the neonatal ABR despite significant effects on birth size.
我们的目的是评估重复产前皮质类固醇治疗对新生儿听觉脑干反应(ABR)的影响,ABR 是评估新生儿脑成熟度和听觉功能的敏感指标。为了实现这一目标,我们在一项多中心随机安慰剂对照临床试验的亚组婴儿中进行了新生儿 ABR 评估,并进行了盲法评估,该试验比较了单疗程与重复疗程产前皮质类固醇治疗对妊娠 23-31 周且仍有早产高风险的妇女的效果。这些妇女被随机分配到单疗程或重复疗程产前皮质类固醇治疗组。重复疗程产前皮质类固醇组的妇女每周接受产前皮质类固醇治疗,直至 34 周妊娠或达到研究确定的疗程数限制,而单疗程产前皮质类固醇组的妇女接受初始疗程皮质类固醇治疗,随后每周注射安慰剂。我们在婴儿出院前对他们进行了 ABR 测试。比较了单疗程(n=27)和重复疗程产前皮质类固醇治疗(n=24)组中波 I、III 和 V 的潜伏期以及波 I 和 V 的峰-谷幅度。尽管重复疗程产前皮质类固醇组的大多数婴儿(24 名中的 20 名)接受了≥4 次产前皮质类固醇治疗,但与单疗程组相比,重复疗程组的婴儿出生体重、身长和头围明显更小(p<0.05)。尽管出生体重存在差异,但 ABR 波潜伏期或幅度在两组之间没有显著差异。我们得出结论,与单次治疗相比,我们的重复产前皮质类固醇治疗尽管对出生体重有显著影响,但对新生儿 ABR 没有显著的益处或危害。